Drug Delivery Systems for Cancer Treatment
A special issue of Bioengineering (ISSN 2306-5354).
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 7113
Special Issue Editors
Interests: drug delivery; biomaterials; biopolymers; hydrogel; tissue engineering; cancer treatment; bioprinting; micro/nanotechnology; nanoparticle biosynthesis
Interests: biomaterials; nanocarriers; stem cells; drug delivery; organ engineering
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer remains a leading cause of death, although significant progresses have been made toward cancer treatment. Novel drug delivery systems are critical toward effective cancer treatment in addition to the discovery of drug molecules themselves. Novel drug delivery systems of various scales and shapes show great promise in improving cancer treatment efficacy, especially in relieving drug resistance. Some state-of-the-art approaches include targeting cancer cells and releasing drugs utilizing tumor microenvironment-responsiveness of the drug carriers. Moreover, drug delivery to cancer stem-like cells needs further research as they are highly involved in drug resistance and metastasis.
This Special Issue on “Novel Drug Delivery Systems for Cancer Treatment” focuses on original research papers and comprehensive reviews which investigate multiscale novel drug delivery systems for effective cancer treatment, especially targeting cancer stem-like cells and drug resistance. Topics of interest for this Special Issue include but are not limited to the following:
- Novel microscale drug delivery systems, such as microspheres and microcapsules, for cancer treatment;
- Novel nanoscale drug delivery systems, such as nanoparticles and nanofibers, for cancer treatment;
- Novel targeted drug delivery systems for cancer treatment;
- Development of in vitro tumor models for anti-cancer therapeutics testing;
- Tumor microenvironment-responsive, such as heat and pH, drug delivery systems for cancer treatment;
- Novel drug delivery systems overcoming cancer cell drug resistance;
- Drug delivery to cancer stem-like cells.
Dr. Wujie Zhang
Prof. Dr. Murugan Ramalingam
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug delivery
- cancer treatment
- controlled release
- sustained release
- drug targeting
- microcarrier
- nanocarrier
- tumor microenvironment-responsive
- cancer stem-like cells
